Feature

Beta Thalassemia: Pricey Gene Therapy Hits The Mark


 

Back on Long Island, a Sense of Relief

Several months after his treatment, Yusuf is doing well. His hemoglobin levels are increasing, and his bone marrow has grown back, his mother said. He’s being home-schooled for the time being because he still faces a risk of infection. (Ms. Ahmed, a stay-at-home mom, has worked a teacher and mosque volunteer. Her husband runs a consumer electronics business.)

As Yusuf gets better, his parents hope they’ll soon be able to take a long trip back home to Pakistan to see relatives. They’ll be able to share their son with family along with something else: a sense of relief.

Dr. Al-Samkari discloses consulting for Agios. Dr. Thompson discloses research for Beam, Bluebird Bio, Editas, Novartis, and Novo Nordisk and consulting for Beam, Bluebird Bio, Editas, Roche, and Vertex.

Pages

Recommended Reading

Focus of new ASH VTE guidelines: Thrombophilia testing
Federal Practitioner
Guide explains nonsurgical management of major hemorrhage
Federal Practitioner
FDA approves first gene therapy for hemophilia A
Federal Practitioner
Hemophilia: Concizumab lessens bleeding, could expand treatment options
Federal Practitioner
CHP/CCUS: Low blood cancer risk for most patients
Federal Practitioner
Nationwide hematologists shortage: What’s being done?
Federal Practitioner
Pediatrician with SCD gives her young patients hope
Federal Practitioner
FDA approves first tx for rare, deadly clotting disorder
Federal Practitioner
Sickle Cell Gene Therapy ‘Truly Transformative’
Federal Practitioner
FDA Approves Second Gene Therapy for Hemophilia B
Federal Practitioner